Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
- PMID: 34481037
- DOI: 10.1016/j.annonc.2021.08.1994
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
Conflict of interest statement
Disclosure JCS reports that he is on the Board of directors for Hookipa Pharma, a former full-time employee of AstraZeneca from September 2017 to December 2019 and has shares in Relay Therapeutics and Gritstone Bio. JR reports receipt of honoraria to institute for consultancy, advisory boards and/or lectures from AstraZeneca, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Merck Sharp & Dohme (MSD), OSE-Immunotherapeutics, Pfizer, Roche. SP reports consultation/advisory roles for AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, BMS, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, MSD, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar, Phosplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody; talk in a company's organised public event: AstraZeneca, Boehringer Ingelheim, BMS, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, MSD, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda; receipt of grants/research support as (sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, BMS, Clovis, F. Hoffmann-La Roche/Genentech, GlaxoSmithKline, Illumina, Lilly, MSD, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical